TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note released on Wednesday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Up 1.3 %

Shares of TXMD stock opened at $1.60 on Wednesday. The firm’s 50-day moving average is $1.70 and its two-hundred day moving average is $1.85. TherapeuticsMD has a 12 month low of $1.43 and a 12 month high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $0.23 million for the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC purchased a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD at the end of the most recent reporting period. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.